HomeOpen Access NewsSH Abivax SA

SH Abivax SA

Subscribe to Updates

ABIVAX: Addressing the need for long-term effective treatments for inflammatory bowel diseases

Diseases & Conditions
Prof. Hartmut J. Ehrlich, MD, CEO of Abivax, explains why the Company’s drug candidate, obefazimod, has the potential to treat Inflammatory Bowel Diseases.

Changing the treatment paradigm in Inflammatory Bowel Diseases

Diseases & Conditions
Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, explains why drug-candidate ABX464 has the potential to address the urgent need for new, safe short- and long-term effective drugs to treat Inflammatory Bowel Diseases.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders

Visit Article Archive
Open Access Government

Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.

Follow Us

Resources

Quick Links

Legal & Marketing

As a Crossref Sponsored Member we are able to connect your content with a global network of online scholarly research, currently over 20,000 other organizational members from 160 countries. Crossref drive metadata exchange and support nearly 2 billion monthly API queries, facilitating global research communication.

© Adjacent Digital Politics Ltd